Bambusa Therapeutics Files S-1 Registration Statement for U.S. IPO
Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process on Nasdaq or NYSE. At 56 MB, it is the largest biotech S-1 filing of the day.
51CFO view：CFO must lead ASC 606 revenue policy design for clinical-stage collaborations, ASC 730 R&D expense/capitalization judgments, and ASC 718 equity award valuation modeling — all while establishing PCAOB-compliant financial systems and audit-ready documentation trails.
Bambusa Therapeutics, Inc. (SEC file no. 0002044950) filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 9, 2026, initiating its IPO process on Nasdaq or NYSE. At 56 MB, it is the largest biotech S-1 filing of the day.
Source：SEC EDGAR · S-1 招股书备案